for morphine-d3 (internal standard). The recoveries ranged from 82 to 89%. The limits of detection were as follows: 0.1 ng/mL (morphine), 0.5 ng/mL (6-MAM), and 1 ng/mL (M3G and M6G).
Introduction
According to our knowledge about heroin metabolism, this drug is at first deacetylated to 6-monoacetylmorphine (6-MAM) and then to morphine. Morphine, in turn, is conjugated in position 3 or 6, yielding morphine-3-glucuronide (M3G) or morphine-6-glucuronide (M6G). Some of the morphine undergoes N-demethylation to normorphine (1, 2) . Taking into consideration the half-lives of these substances in blood, in every * Author to whom correspondence should be addressed.
case of fatal heroin intoxication with short survival time, at least four metabolites are present in humans: morphine, 6-MAM, M3G, and M6G. Theoretically, other intermediate metabolites, such as 3-monoacetylmorphine, 6-monoacetylmorphine-3-glucuronide, and 3-monoacetylmorphine-6-glucuronide, are also possible.
The pharmacological activity of M6G has been known for a long time (3) (4) (5) (6) (7) (8) . The introduction of high-pressure liquid chromatography (HPLC) methods for the analysis of morphine glucuronides enabled the direct monitoring of M3G and M6G after morphine administration (9) (10) (11) (12) (13) . It appears that M6G may accumulate in the organism in the case of kidney insufficiency and may be responsible for morphine toxicity among chronically medicated patients (14) (15) (16) . The possible role of M6G in heroin toxicity has also been discussed (17) . The toxicological relevance of M3G is not clear. The reports on its antagonistic activity in relation to morphine are equivocal (18) (19) (20) . M3G may influence the rate of glucuronidation of morphine, which leads to the prolongation of analgesic effect of morphine (21) . Observed differences in biological activity of morphine and its glucuronides brought some authors to the conclusion that the molar ratio of glucuronides might be responsible for the antinociceptive effect of morphine (22) .
In recent years, morphine and its glucuronides have been measured in autopsy blood samples taken from heroin victims. Molar ratios between M6G or M3G and morphine were lower in fatal heroin overdose (7 cases) than among living addicts (19 cases) (23) . In our previous study, the ratios between M3G and morphine were lower among 16 deceased heroin addicts when compared with the values observed among cancer patients receiving oral morphine (24) . The absolute concentrations of M6G were higher among heroin victims in both studies. In another study, nine blood samples taken from deceased heroin abusers were investigated; M6G was detected in six cases (25) .
In all of the previously mentioned investigations, HPLC with ultraviolet, electrochemical, or fluorimetric detection was used. These detectors, although sensitive, have low specificity, which may affect the results, particularly in postmortem blood samples (24) . These difficulties prompted some authors to use combined detection techniques such as IN and electrochemical detection or IN and fluorimetry (11, 13, 25) .
Atmospheric pressure chemical ionization-liquid chromatography-mass spectrometry (APCI-LC-MS), used in pilot experiments in the previous study, appeared much more specific (24) . This method--in electrospray option--was applied by Pacifici et al. (26) for determination of serum samples of heroin addicts. Surprisingly, M6G was detected in only one out of five cases. Recently, Tyrefors et al. (27) applied electrospray LC-MS with external standardization for determination of morphine and its glucuronides among patients receiving morphine.
The purpose of the present study was to measure the levels of morphine, 6-MAM, M3G, and M6G in body fluids of fatally intoxicated heroin addicts by means of APCI-LC-MS. It was assumed that the comparison of the concentrations and molar ratios of morphine and its glucuronides in blood among the victims with different survival times could reveal some relevant differences. The study also gave the opportunity to compare the present results with those obtained with less specific methods. The determination of 6-MAM was included because its presence proves the use of heroin (28) (29) (30) . Assuming a short half-life of 6-MAM in blood, its concentration may supply additional informations concerning the mode of death (rapid or delayed) (31) .
Material and Methods

Materials
Autopsy samples. Blood samples (n = 21) from the femoral vein, 11 samples of cerebrospinal fluid (CSF), 12 samples of vitreous humor (VII), and 6 samples of urine were taken from 21 persons fatally intoxicated with heroin and examined in the Institute of Forensic Medicine in Aachen. The materials taken during autopsy were immediately frozen and stored at -20~ until examination. An acute heroin overdose was stated as a cause of death in all cases. Table I presents some available data concerning these subjects.
Reagents. M3G, M6G, morphine, 6-MAM, and deuterated morphine (morphine-d3) were supplied by Sigma Chemical (St. Louis, MO). Solid-phase extraction (SPE) columns (Bond Elut C18, 200 rng, endcapped, ICT GmbH, Frankfurt, Germany) were activated by passing 1 mL methanol, 1 mL water, and 2 rnL 0.01M ammonium carbonate buffer (pH 9.3) through the columns before use.
Accuracy and precision standards. Blood and serum samples spiked with morphine, M3G, M6G, and 6-MAM in the concentration range of 5 to 500 ng/mL were used as accuracy and calibration standards. Medidrug Opiate S-X serum (Medichem, Stuttgart, Germany), spiked with morphine, M3G, and M6G (assigned values 80 to 120 ng/mL), was used for precision control.
Methods
Extraction. Samples (1.0 mL) of biological fluid were mixed with 2 mL of 0.01M ammonium carbonate buffer (pH 9.3) containing 100 ng morphine-d3 (internal standard). The samples were vortex mixed for 30 s and centrifuged for 10 rain at 10,000 x g. Supernatant (2 rnL) was applied on the activated SPE columns and slowly passed through them. The columns were rinsed with 3 rnL 0.01M ammonium carbonate buffer and dried for 5 rain under vacuum. The analytes were eluted with 0.5 mL methanol-0.5N acetic acid (9:1) under gravity. The eluates were dried at 25~ under nitrogen, reconstituted in 100 pL mobile phase, and centrifuged for 3 rnin at 10,000 xg. Supernatant (20 pL) was injected onto the chromatograph.
HPLC. The mobile phase used for morphine, M3G, and M6G consisted of 50rnM ammonium formate buffer (pH 3.0) and acetonitrile (95:5). For 6-MAM, the mixture of 50raM ammonium formate buffer (pH 3.0) and acetonitrile (90:10) was used. The flow rate of 0.6 mL/min was applied for both phases.
The column used was an Ecocart cartridge (125 x 3 ram) filled with Superspher Select B (E. Merck, Darmstadt, Germany).
APCI-LC-M$. An SSQ 7000 instrument (Finnigan MAT, San Jose, CA) was used in positive ionization mode. For the fragmentation study of morphine, 6-MAM, and glucuronides, full scan spectra were taken in the mass range rn/z 100 to 500 at 1-s scan time using the octapol voltages of 10 V and 40 V. At 10 V, the molecules of M3G and M6G underwent fragmentation because of collision-induced dissociation (CID). The molecules of 6-MAM were partially fragmented at 40 V. On the basis of M6G, morphine-6-glucuronide; IS, internal standard. + For the study of recoveries, the mixture containing 13 ng of each analyte and IS per 20 pL of mobile phase was injected into LC-MS. The recoveries were calculated from the ratios drug-iS in extracted serum samples containing 100 ng/mL of each drug versus the ratios drug-IS in standard mixture. Mean value + SD of five experiments. * The limit of detection was set at signal-to-noise ratio of 3. Double limit of detection was used as a limit of quantitation.
information obtained from the full scan runs, the procedures were written for the monitoring of relevant ions. In the first procedure, which was applied for morphine and its glucuronides, the ions m/z 286 (protonated molecular ion of morphine and most distinct fragments of M3G and M6G), rn/z 289 (protonated molecular ion of morphine-d3), and m/z 462 (protonated molecular ions of M3G and M6G) were monitored using the octapole voltage of 10 V and scan time of 0.5 s (Figure 1 ). In the second procedure, for 6-MAM, the ions m/z 328, 268, and 211 (protonated molecular ion of 6-MAM and two fragments) and m/z 289 (morphine-d3) were scanned using the octapole voltage of 40 V and scan time of 0.5 s (Figure 2 ). Quantitation. The calibrations curves for all analytes consisted of five points, which covered the range of 5 to 500 ng/mL. The calculations were made using the internal standardization method. For the quantitation of morphine, M3G, and M6G, the area ratios rn/z 286/289 of respective peaks were used. The ions m/z 462 were used for the confirmation of identity. For the calculation of 6-MAM concentration, the area ratio rn/z 328/289 was applied, and the fragments m/z 211 and 268 were used as qualifiers.
Validation. In the preliminary study, blank serum, blood, urine, and CSF samples were spiked with a mixture containing 50 ng/mL of each drug and subjected to extraction and LC-MS analysis. The results of quantitative analysis showed virtually no differences between these matrices. Therefore, only serum standards were used for further validation experiments. The method was validated by repetitive (5 times on different days) analysis of spiked serum standards containing 5, 10, 50, 100, and 500 ng/mL of each analyte. After analysis, the extracts were frozen at -20~ and stored for 6 weeks. The stability was investigated by the analysis of all compounds in a given extract in 1-week intervals and the comparison of results with the primary values.
Results and Discussion
Fragmentation of compounds by means of CID
Full-scan LC-MS spectra of morphine and morphine-d3 showed protonated molecular ions (m/z 286 for morphine and
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The molecules of M3G and M6G were partially fragmented to protonated morphine (m/z 286). Protonated molecular ions (m/z 462) were also observed. The 6-MAM molecule was fragmented in small proportion to m/z 211 and 268. The protonated molecular ion (m/z 328) appeared as a base peak (Figure 3 ).
Validation
The validation was performed in selected ion monitoring conditions, using two procedures (for morphine, M3G, and M6G, and for 6-MAM, respectively). The same procedures were used for the quantitation of analytes in forensic samples throughout the entire study. Table II shows the standard curves, recoveries, and detection limits. The day-to-day precision, determined by fivefold determination of serum precision standard, averaged 6% RSD for morphine, 9% for M3G and M6G, and 7% for 6-MAM.
Repetitive examination of extracts, reconstituted in mobile phase and stored at-20~ showed no significant changes in all analytes during 4 weeks of storage. After this time, a decline in both glucuronide levels was observed. This is in agreement with the observations of Fuller et al. (30) , who found that 6-MAM levels were stable for 12 weeks when stored at -17~
Examination of forensic samples
The results of all measurements are listed in the Table III. The concentrations of all analytes in particular body fluids were widely scattered. This was observed also by other authors (23) (24) (25) 31, 32) and may be caused by several factors, such as individual susceptibility to opiates, different survival times, or coexistence of other toxic factors.
The concentrations of morphine showed weak but significant correlation with the concentrations of both M3G (r = 0.5305) and M6G (r = 0.3253). The concentrations of M3G and M6G were not correlated.
The comparison of the present blood values with data observed by other authors among heroin addicts and patients receiving morphine is shown in the Table IV. One striking difference between data for heroin victims and patients receiving morphine chronically concerns the degree of glucuronidation to M3G, which was much more pronounced among the patients. High concentrations of free morphine and low ratios of M3G-morphine and M6G-morphine in heroin-related death cases are understandable in the view of pharmacokinetical data and reflect short survival times after heroin intake. Osborne et al. (33) demonstrated that the metabolism of morphine to glucuronides proceeded rapidly and the levels of M3G and M6G may exceed that of free morphine approximately 0.5 h after intravenous application.
Some authors confronted the results of opiate determinations with the estimated survival time in heroin-related deaths. Goldberger et al. (31) investigated 21 cases, among them were 8 rapid deaths (within 15 min of drug administration), 7 delayed deaths (after several hours), and 6 of undetermined duration. The percentage of free morphine in rapid-death cases was higher (53%) than in delayed-death cases (34%). In rapid-death cases, the concentrations of free morphine, 6-MAM, and total opiates in blood were higher than in delayed deaths. The likelihood of 6-MAM detection in blood was higher, and the levels of morphine and 6-MAM were lower in urine in rapid-death cases. Spiehler (32) performed computer-assisted analysis of case data from 200 morphine-involved death cases using three artificial-intelligence softwares. In all the material, free morphine in blood exceeded 240 ng/mL, the percentage of free morphine was greater than 37%, and the brain total morphine was higher than 80 ng/mL. In rapid-death cases (within 3 h), free morphine in blood was greater than 90-210 ng/mL, the percentage of free morphine was over 44-50%, and brain total morphine higher than was 90-210 ng/mL. In undertaking the confrontation of the analytical data with existing information concerning the circumstances of death, one must be conscious of limited reliability and scarcity of such data. Heroin victims usually die without any witnesses or in the presence of companions whose credibility is questionable. Therefore, in the present material, an opposite approach was used; the analytical data were taken as a basis for classification as "rapid" and "delayed" death cases. Among 21 blood samples, three of them (9, 15 , and I6) showed low levels of free morphine and high ratios of both glucuronides. These cases (particularly 9) were unequivocally "delayed" deaths. On the contrary, in five cases (2, 6, 17, 18, and 20) , a high percentage of free morphine was demonstrated. Among these cases, two of them (18 and 20) concerned suicidial heroin poisonings. In case 6, the estimated survival time was not longer than I h. In case 2, the estimated survival time was not longer than 4 h, and no information was available for case 17.
In all 11 available CSF samples, morphine and both glucuronides were found. The concentrations of M6G in CSF were correlated with the respective blood values (r = 0.6099). Also, the molar ratios of morphine-M6G in blood and CSF were very strongly correlated (r = 0.9919). In 10 out of 11 cases, the absolute concentrations of M6G in blood were higher than in CSF (1.6-9.4 times), and, in one case, they were practically identical.
Hence, the study showed significant concentrations not only of morphine, but also its active metabolite, M6G, in CSF taken from heroin victims. These findings are concordant with the available experimental and clinical data, which were obtained from patients medicated with morphine. Hand et al. (37) found M6G in CSF of cancer patients treated orally with morphine in concentrations of approximately 13% of the blood value. Approximately 85% of the analgetic action of morphine may derive from M6G, based on the central nervous system potency of M6G. Hanks et al. (38) mentioned that the ratio of M6G--morphine in CSF taken from cancer patients was approximately 2:1. Portenoy et al. (39) measured morphine and M6G concentrations in the plasma and either ventricular or lumbar CSF of patients receiving chronic morphine therapy. Significant correlations between the concentrations of both morphine and death cases (6.7 + 10.9 ng/mL). In the same study, the concentrations of 6-MAM in CSF, which were determined in two cases, were higher than in blood. In only one case (#1) in the present study did the level of 6-MAM in CSF exceed the blood Reference value, and in five cases it was lower. Moeller and Mueller (44) In the sudden-death case of a heroin body packer 35 (46) , the blood 6-MAM concentration amounted to 36 184 mg/L and was higher than that of morphine, 23 which was 120 mg/L. In the present material, case 24 #18 showed a particularly high concentration of 6-MAM. In the same case, the concentration of free 25 morphine was very high, and the ratios of M3G-morphine and M6G-morphine were the current lowest. These parameters together may indicate a study particularly short survival time after heroin injection. The concentrations of 6-MAM in urine samples showed large variation and were generally much higher than the blood values. These findings were concordant with the existing reports (28, 31, 44) .
It may be generally stated that the application of APCI-LC-MS brought new quality to the detection of morphine glucuronides in biological fluids. The method was much more selective than electrochemical detection and showed comparable sensitivity. Over several months of routine use, APCI-LC-MS proved to be a very robust and forgiving technique. It seems that the APCI-LC-MS instrumentation has reached its maturity and may be applied for everyday use in routine casework. M6G in plasma and in CSF were observed. The absolute concentrations of M6G in CSF and molar ratios M6G-morphine were about ten times lower than in plasma. On the contrary, Stain et al. (40) demonstrated that the maximal concentrations were higher for M6G than for morphine both in brain extracellular fluid and in blood of rats after subcutaneous administration of both drugs. Murphey and Olsen (41) observed that morphine glucuronides in brain or CSF of guinea pigs may originate from two sources: glucuronidation of morphine in the central nervous system and diffusion through the blood-brain barrier. Logan and L•thi (42) determined morphine in blood and CSF taken from victims of heroin overdose. The values in both fluids were poorly correlated. The morphine ratio of CSF-blood ranged from 0.28 to 1.82. The CSF morphine concentrations higher than 20 ng/mL were found to be consistent with morphine-related respiratory depression. In the present study, the concentrations of morphine in CSF distinctly exceeded the value of 20 ng/mL in 10 out of 11 cases. In one case (case 9) with low morphine concentrations in blood, CSF, and VII, the concentrations of M6G were fairly high. The concentrations of morphine in blood and CSF were highly correlated (r = 0.9610). For the sake of comparison, the data from Logan and Smirnow (43) were recalculated, and a correlation between morphine in blood and CSF was found (r = 0.6330).
The concentrations of morphine and its glucuronides in VH were distinctly lower than in blood and in CSE This may reflect a slower distribution of drugs to vitreous humor.
The concentrations of 6-MAM in blood ranged from 0 to 73 ng/mL and were correlated with the concentrations of morphine and M3G (r = 0.8739 and 0.5504, respectively) but not M6G. There are few available data concerning the concentrations of 6-MAM in blood of heroin addicts. Goldberger et al. (31) observed blood 6-MAM concentrations from 0 to 82.9 ng/mL among 21 heroin victims. Higher concentrations were measured in rapid-death cases (18.9 • 28.0 ng/mL) than in delayed-
Conclusion
Several conclusions may be drawn from the study. APCI-LC-MS appeared to be a selective, sensitive, and robust method for the determination of the heroin metabolites 6-MAM and morphine and its glucuronides in postmortem biological fluids. The ratio of biologically active M6G to M3G seemed to be higher in heroin fatalities than during oral morphine therapy. Morphine and both of its glucuronides and 6-MAM were found in cerebrospinal fluid. The concentrations of morphine and M6G and their molar ratios in cerebrospinal fluid correlated with the blood values. The concentrations of morphine, M6G, and M3G in vitreous humor were distinctly lower than in blood and CSE A high proportion of free morphine in blood and CSF together with high 6-MAM in blood indicated short survival time after heroin intake.
